Vimarsana
Biggest News Aggregation in the World

Page 3 - Nirvi Ashar News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nirvi Ashar. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nirvi Ashar Today - Breaking & Trending Today

Headed for a rise or fall? Here's where 7 experts see the auto space going in next 6 months - Vimarsana News

Headed for a rise or fall? Here's where 7 experts see the auto space going in next 6 months

Going ahead most analysts have mixed views on the space. While the pent-up demand is fading and the sector is facing rising interest rates and further price hikes expected the export; However, margin improvement is expected due to a decrease in commodity prices and price hikes.

Windlas Biotech IPO: Windlas Biotech offers its shares at 64x PE. Should you subscribe? - Vimarsana News

Windlas Biotech IPO: Windlas Biotech offers its shares at 64x PE. Should you subscribe?

NEW DELHI: Analysts tracking primary issues believe one can subscribe to the initial public offering of Windlas Biotech, a Contract Development Manufacturing Organisation (CDMO), for the long term. The issue opens for subscription today. The Dehradun-based firm will raise Rs 165 crore through issuance of fresh equity shares, while the promoters and existing shareholders will offload 51,42,067 equity shares worth Rs 236 crore via an offer-for-sale (OFS). The price band for the issue is fixed at Rs 448-460 per share. “Windlas is focusing on formulation CDMO, and there is no peer company focus...

Suryoday IPO: Risky bet, aggressively priced: Should you subscribe to Suryoday SFB IPO? - Vimarsana News

Suryoday IPO: Risky bet, aggressively priced: Should you subscribe to Suryoday SFB IPO?

NEW DELHI: The initial public offering (IPO) of Suryoday Small Finance Bank opened for bidding on Wednesday alongside the issue of Nazara Technologies. Analysts seem to have mixed views on the issue, with some pointing to the significant risks that it carries. The company seeks to raise Rs 581 crore. The primary purpose of the IPO is to meet RBI’s listing requirement within three years of starting banking operations. Unfortunately, it’s being forced to launch its issue amid a pandemic that has left it with more than a few chinks in the armour. Rajiv Mehta, Lead Analyst for Institutional E...